Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan
After the launch of dipeptidyl peptidase-4 (DPP-4), a new oral hypoglycemic drug (OHD), in December 2009, severe hypoglycemia cases were reported in Japan.Although the definite cause was unknown, co-administration with sulfonylureas (SU) was suspected as one of the potential risk factors.The Japan Association for Diabetes Education and Care (JADEC)